アンチセンスとRNAi治療薬の世界市場レポート 2025年

アンチセンスとRNAi治療薬市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）13.1％で31億8,000万米ドルに成長します。予測期間の成長は、ヘルスケアへのアクセスの増加、がん有病率の上昇、COVID-19によるアンチセンスおよびRNAi治療薬の需要増に起因すると考えられます。予測期間の主な動向としては、希少疾患向けRNA治療薬の研究開発への注力、ナノ粒子の使用、新規および改良型アンチセンスおよびRNAi治療薬の開発、製品の革新と収益促進のための他社との提携などが挙げられます。

冠動脈疾患、神経変性疾患、感染症の有病率の増加は、アンチセンスおよびRNAi治療薬市場の需要を押し上げると予想されます。RNA干渉やアンチセンス・オリゴヌクレオチドのような遺伝子抑制技術は、変異遺伝子を修復することによって様々な神経変性疾患を治療するために利用されています。例えば、米国心臓協会が2024年1月に発表した報告によると、心血管疾患による年齢調整死亡率は10万人当たり233.3人となり、前年から4.0％増加しました。したがって、神経変性疾患や感染症の罹患率の増加がアンチセンスおよびRNAi治療薬市場の成長を促進すると予想されます。

慢性疾患の有病率の増加は、アンチセンスおよびRNAi治療薬市場の需要を促進すると予想されます。慢性疾患は、治癒不可能な長期的な健康状態であり、心血管疾患、腫瘍性疾患などの病気を包含します。アンチセンスおよびRNA干渉（RNAi）治療薬は、これらの病態の病因に関連する特定の遺伝子や分子経路を標的とすることで、さまざまな心血管疾患を治療する可能性を示しています。例えば、米国の専門機関である世界保健機関（WHO）が発表した『World Heart Report 2023』では、2021年には約2,050万人が心血管疾患で死亡し、その年の世界全体の死亡者数の約3分の1を占めることが明らかにされています。したがって、慢性疾患の有病率の上昇は、アンチセンスおよびRNAi治療薬市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アンチセンスとRNAi治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のアンチセンスとRNAi治療薬市場：成長率分析
• 世界のアンチセンスとRNAi治療薬市場の実績：規模と成長, 2019-2024
• 世界のアンチセンスとRNAi治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界アンチセンスとRNAi治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアンチセンスとRNAi治療薬市場：技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• RNA干渉
• アンチセンスRNA
• 世界のアンチセンスとRNAi治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 静脈注射
• 皮内注射
• その他の配送方法
• 世界のアンチセンスとRNAi治療薬市場適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 心血管疾患（CVD）
• 呼吸器疾患
• 神経疾患
• 感染症
• その他の適応症
• 世界のアンチセンスとRNAi治療薬市場RNA干渉（RNAi）のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分子干渉RNA（siRNA）
• ショートヘアピンRNA（shRNA）
• ダイサー基質siRNA
• マイクロRNA（miRNA）ベースの治療法
• 世界のアンチセンスとRNAi治療薬市場アンチセンスRNAのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アンチセンスオリゴヌクレオチド（ASO）
• モルホリノオリゴマー
• ロックド核酸（LNA）
• ギャップマーアンチセンスオリゴヌクレオチド

第7章 地域別・国別分析

• 世界のアンチセンスとRNAi治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアンチセンスとRNAi治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アンチセンスとRNAi治療薬市場：競合情勢
• アンチセンスとRNAi治療薬市場：企業プロファイル
  • Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Dicerna Pharmaceuticals Inc.
• Arbutus Biopharma Corporation
• Acuitas Therapeutics
• Adhera Therapeutics Inc.
• EdiGene Inc.
• Sirnaomics Inc.
• Suzhou Ribo Life Science Co. Ltd
• Biocon Limited
• Quark Pharmaceuticals
• GlaxoSmithKline Plc
• Shanghai Junshi Biosciences Co. Ltd.
• AstraZeneca
• Benitec Biopharma Limited
• Silence Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アンチセンスとRNAi治療薬市場2029：新たな機会を提供する国
• アンチセンスとRNAi治療薬市場2029：新たな機会を提供するセグメント
• アンチセンスとRNAi治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Antisense therapy involves the targeted and sequence-specific suppression of gene expression using single-stranded DNA oligonucleotides. In contrast, RNA interference (RNAi) is triggered by double-stranded RNA (dsRNA) and leads to the sequence-specific degradation of single-stranded target RNAs.

The primary technologies in antisense and RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA, which plays a role in resisting both endogenous parasitic and exogenous pathogenic nucleic acids, and it regulates the expression of protein-coding genes. Various routes of administration for these therapies include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other methods. These therapies are used for indications such as oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, and others.

The antisense & RNAi therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The antisense & RNAi therapeutics market size has grown rapidly in recent years. It will grow from $1.75 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to a rise in funding, advancement in technologies, and rise in healthcare expenditure, rapid growth in the elderly population, and economic growth in emerging markets.

The antisense & RNAi therapeutics market size is expected to see rapid growth in the next few years. It will grow to $3.18 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to an increase in healthcare access, rising prevalence of cancer, and increasing demand for antisense and RNAi therapeutics due to COVID-19. Major trends in the forecast period include focus efforts towards the research and development of RNA therapeutics for orphan diseases, use of nanoparticles, development of new and improved antisense and RNAi therapeutics, and collaboration with other companies for product innovation and to drive revenues.

The increasing prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is expected to boost demand for the antisense and RNAi therapeutics market. Gene suppression techniques, such as RNA interference and antisense oligonucleotides, are utilized to treat various neurodegenerative conditions by repairing mutant genes. For example, a report from the American Heart Association, a U.S.-based organization, published in January 2024, indicated that the age-adjusted death rate from cardiovascular diseases rose to 233.3 per 100,000, marking a 4.0% increase from the previous year. Therefore, the growing incidence of neurodegenerative and infectious diseases is anticipated to drive the growth of the antisense and RNAi therapeutics market.

The increasing prevalence of chronic diseases is expected to drive demand for the antisense and RNAi therapeutics market. Chronic diseases are long-term health conditions that cannot be cured, encompassing illnesses such as cardiovascular diseases, oncological disorders, and others. Antisense and RNA interference (RNAi) therapeutics have demonstrated potential in treating various cardiovascular diseases by targeting specific genes or molecular pathways linked to the pathogenesis of these conditions. For example, the World Heart Report 2023, published by the World Health Organization (WHO), a U.S.-based specialized agency, revealed that in 2021, approximately 20.5 million individuals died from cardiovascular conditions, accounting for roughly one-third of all global deaths that year. Therefore, the rising prevalence of chronic diseases is anticipated to propel the growth of the antisense and RNAi therapeutics market.

Major companies in the antisense & RNAi therapeutics sector are employing strategic collaborations and partnerships as key initiatives to maintain their positions in an increasingly competitive market landscape. These partnerships involve joint efforts between two or more companies aiming to achieve shared objectives. For instance, in January 2023, Orbit Discovery Limited, a US-based company specializing in peptide discovery services, teamed up with SanegeneBio Inc., a UK-based firm focused on developing innovative RNAi-based medicines. This collaboration aims to identify tissue-specific delivery of RNA therapeutics for efficient gene knockdown. The partnership involves hit identification and cell-based internalization studies, leveraging Orbit's proprietary technology for rapid peptide lead discovery. Sanegene gains the opportunity to further develop potential hits derived from the screening activities for advanced RNAi therapeutics.

Major players in the antisense & RNAi therapeutics market are fostering partnerships to forge new relationships aimed at jointly creating innovative products. These strategic collaborations represent cooperative alliances between organizations, pooling their strengths or resources toward common goals. For example, in December 2022, GlaxoSmithKline (GSK), a UK-based pharmaceutical giant, and Wave Life Sciences, a US-based company specializing in genetic medicines, announced a collaboration to develop oligonucleotide therapeutics targeting novel genetic markers. By integrating GSK's genetic expertise with Wave's PRISM platform, the collaboration aims to advance up to eight preclinical programs. Additionally, GSK secures an exclusive global license for Wave's WVE-006, a potential RNA editing program targeting alpha-1 antitrypsin deficiency (AATD). Wave's PRISM platform uniquely offers three RNA-targeting modalities, leveraging innovative chemistry to optimize the properties of therapeutic oligonucleotides.

In July 2023, Alnylam, a U.S.-based biopharmaceutical company specializing in RNAi therapeutics, announced a strategic partnership with Roche, a Switzerland-based global healthcare company that develops medicines, diagnostics, and treatments. The partnership involves an initial investment of $310 million, with the total deal value potentially reaching up to $2.8 billion through various development, regulatory, and sales milestones. As part of this collaboration, the companies will co-develop and co-commercialize Zilebesiran, an investigational RNAi therapeutic aimed at treating hypertension in patients at high cardiovascular risk. This partnership combines Alnylam's expertise in RNAi therapeutics with Roche's extensive experience in drug development and commercialization, potentially transforming treatment options for patients with hypertension and high cardiovascular risk.

Major companies operating in the antisense & RNAi therapeutics market include Biogen Inc., Ionis Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Moderna Inc., Sanofi S.A., Dicerna Pharmaceuticals Inc., Arbutus Biopharma Corporation, Acuitas Therapeutics, Adhera Therapeutics Inc., EdiGene Inc., Sirnaomics Inc., Suzhou Ribo Life Science Co. Ltd, Biocon Limited, Quark Pharmaceuticals, GlaxoSmithKline Plc, Shanghai Junshi Biosciences Co. Ltd., AstraZeneca, Benitec Biopharma Limited, Silence Therapeutics, Dynacure, CN Bio Innovations, Sarepta Therapeutics, Mallinckrodt, Regeneron Pharmaceuticals Inc., Alcyone Lifesciences Inc., Bio-Path Holdings Inc, Calando Pharmaceuticals, Enzon Pharmaceuticals Inc, Celnova Pharma, Pfizer Inc., Taiba Pharma, Gen Ilac ve SaglIk Urunleri A.S., Egypt Otsuka Pharmaceutical

North America was the largest region in the antisense & RNAi therapeutics market in 2024. The regions covered in the antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Antisense & RNAi Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antisense & rnai therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antisense & rnai therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The antisense & rnai therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Technology: RNA Interference, Antisense RNA
• 2) By Route Of Administration: Intravenous Injections, Intra-dermal Injections, Other Delivery Methods
• 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications
• Subsegments:
• 1) By RNA Interference (RNAi): Small Interfering RNA (siRNA); Short Hairpin RNA (shRNA); Dicer-substrate siRNA; MicroRNA (miRNA) Based Therapeutics
• 2) By Antisense RNA: Antisense Oligonucleotides (ASOs); Morpholino Oligomers; Locked Nucleic Acids (LNAs); Gapmer Antisense Oligonucleotides
• Companies Mentioned: Biogen Inc.; Ionis Pharmaceuticals Inc.; Alnylam Pharmaceuticals Inc.; Arrowhead Pharmaceuticals Inc.; Moderna Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Antisense & RNAi Therapeutics Market Characteristics

3. Antisense & RNAi Therapeutics Market Trends And Strategies

4. Antisense & RNAi Therapeutics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Antisense & RNAi Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Antisense & RNAi Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Antisense & RNAi Therapeutics Market Growth Rate Analysis
• 5.4. Global Antisense & RNAi Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Antisense & RNAi Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Antisense & RNAi Therapeutics Total Addressable Market (TAM)

6. Antisense & RNAi Therapeutics Market Segmentation

• 6.1. Global Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA Interference
• Antisense RNA
• 6.2. Global Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous Injections
• Intra-dermal Injections
• Other Delivery Methods
• 6.3. Global Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Cardiovascular Diseases (CVDs)
• Respiratory Disorders
• Neurological Disorders
• Infectious Diseases
• Other Indications
• 6.4. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of RNA Interference (RNAi), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Interfering RNA (siRNA)
• Short Hairpin RNA (shRNA)
• Dicer-substrate siRNA
• MicroRNA (miRNA) Based Therapeutics
• 6.5. Global Antisense & RNAi Therapeutics Market, Sub-Segmentation Of Antisense RNA, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antisense Oligonucleotides (ASOs)
• Morpholino Oligomers
• Locked Nucleic Acids (LNAs)
• Gapmer Antisense Oligonucleotides

7. Antisense & RNAi Therapeutics Market Regional And Country Analysis

• 7.1. Global Antisense & RNAi Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Antisense & RNAi Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Antisense & RNAi Therapeutics Market

• 8.1. Asia-Pacific Antisense & RNAi Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Antisense & RNAi Therapeutics Market

• 9.1. China Antisense & RNAi Therapeutics Market Overview
• 9.2. China Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Antisense & RNAi Therapeutics Market

• 10.1. India Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Antisense & RNAi Therapeutics Market

• 11.1. Japan Antisense & RNAi Therapeutics Market Overview
• 11.2. Japan Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Antisense & RNAi Therapeutics Market

• 12.1. Australia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Antisense & RNAi Therapeutics Market

• 13.1. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Antisense & RNAi Therapeutics Market

• 14.1. South Korea Antisense & RNAi Therapeutics Market Overview
• 14.2. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Antisense & RNAi Therapeutics Market

• 15.1. Western Europe Antisense & RNAi Therapeutics Market Overview
• 15.2. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Antisense & RNAi Therapeutics Market

• 16.1. UK Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Antisense & RNAi Therapeutics Market

• 17.1. Germany Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Antisense & RNAi Therapeutics Market

• 18.1. France Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Antisense & RNAi Therapeutics Market

• 19.1. Italy Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Antisense & RNAi Therapeutics Market

• 20.1. Spain Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Antisense & RNAi Therapeutics Market

• 21.1. Eastern Europe Antisense & RNAi Therapeutics Market Overview
• 21.2. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Antisense & RNAi Therapeutics Market

• 22.1. Russia Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Antisense & RNAi Therapeutics Market

• 23.1. North America Antisense & RNAi Therapeutics Market Overview
• 23.2. North America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Antisense & RNAi Therapeutics Market

• 24.1. USA Antisense & RNAi Therapeutics Market Overview
• 24.2. USA Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Antisense & RNAi Therapeutics Market

• 25.1. Canada Antisense & RNAi Therapeutics Market Overview
• 25.2. Canada Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Antisense & RNAi Therapeutics Market

• 26.1. South America Antisense & RNAi Therapeutics Market Overview
• 26.2. South America Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Antisense & RNAi Therapeutics Market

• 27.1. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Antisense & RNAi Therapeutics Market

• 28.1. Middle East Antisense & RNAi Therapeutics Market Overview
• 28.2. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Antisense & RNAi Therapeutics Market

• 29.1. Africa Antisense & RNAi Therapeutics Market Overview
• 29.2. Africa Antisense & RNAi Therapeutics Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Antisense & RNAi Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Antisense & RNAi Therapeutics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Antisense & RNAi Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Antisense & RNAi Therapeutics Market Competitive Landscape
• 30.2. Antisense & RNAi Therapeutics Market Company Profiles
  • 30.2.1. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Ionis Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Arrowhead Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Antisense & RNAi Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Dicerna Pharmaceuticals Inc.
• 31.3. Arbutus Biopharma Corporation
• 31.4. Acuitas Therapeutics
• 31.5. Adhera Therapeutics Inc.
• 31.6. EdiGene Inc.
• 31.7. Sirnaomics Inc.
• 31.8. Suzhou Ribo Life Science Co. Ltd
• 31.9. Biocon Limited
• 31.10. Quark Pharmaceuticals
• 31.11. GlaxoSmithKline Plc
• 31.12. Shanghai Junshi Biosciences Co. Ltd.
• 31.13. AstraZeneca
• 31.14. Benitec Biopharma Limited
• 31.15. Silence Therapeutics

32. Global Antisense & RNAi Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Antisense & RNAi Therapeutics Market

34. Recent Developments In The Antisense & RNAi Therapeutics Market

35. Antisense & RNAi Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Antisense & RNAi Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Antisense & RNAi Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Antisense & RNAi Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer